Raymond James Financial Services Advisors Inc. continued to hold its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,161 shares of the biotechnology company’s stock at the close of the 2nd quarter. Raymond James Financial Services Advisors Inc.’s holdings in Ironwood Pharmaceuticals were worth $230,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Teacher Retirement System of Texas purchased a new stake in shares of Ironwood Pharmaceuticals in the second quarter valued at approximately $192,000. Strs Ohio boosted its holdings in shares of Ironwood Pharmaceuticals by 63.1% in the second quarter. Strs Ohio now owns 10,600 shares of the biotechnology company’s stock valued at $200,000 after purchasing an additional 4,100 shares during the period. KCG Holdings Inc. boosted its holdings in shares of Ironwood Pharmaceuticals by 20.5% in the first quarter. KCG Holdings Inc. now owns 14,270 shares of the biotechnology company’s stock valued at $243,000 after purchasing an additional 2,428 shares during the period. Aperio Group LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 11.9% in the second quarter. Aperio Group LLC now owns 13,213 shares of the biotechnology company’s stock valued at $249,000 after purchasing an additional 1,410 shares during the period. Finally, Virtu KCG Holdings LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 10.3% in the second quarter. Virtu KCG Holdings LLC now owns 15,740 shares of the biotechnology company’s stock valued at $297,000 after purchasing an additional 1,470 shares during the period. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) opened at $15.25 on Friday. The company has a current ratio of 4.87, a quick ratio of 4.86 and a debt-to-equity ratio of -22.31. Ironwood Pharmaceuticals, Inc. has a 12-month low of $13.43 and a 12-month high of $19.94.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.07. The business had revenue of $86.80 million for the quarter, compared to the consensus estimate of $73.59 million. Ironwood Pharmaceuticals had a negative return on equity of 645.22% and a negative net margin of 48.89%. The business’s quarterly revenue was up 31.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.18) earnings per share. equities research analysts anticipate that Ironwood Pharmaceuticals, Inc. will post -1.12 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/12/raymond-james-financial-services-advisors-inc-holds-stake-in-ironwood-pharmaceuticals-inc-irwd.html.

A number of equities analysts recently commented on IRWD shares. Cowen and Company set a $20.00 price objective on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 4th. Mizuho reissued a “buy” rating and issued a $23.00 price objective (up previously from $22.00) on shares of Ironwood Pharmaceuticals in a research note on Wednesday, August 2nd. Wells Fargo & Company set a $19.00 price objective on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, July 22nd. BidaskClub downgraded shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Finally, Zacks Investment Research raised shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 17th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $18.29.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Stock Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.